Tiredness News and Research

RSS

Cocoa can benefit patients with multiple sclerosis

A new study has shown that drinking hot chocolate daily could help to reduce fatigue and tiredness among people suffering from MS (multiple sclerosis). The results of this new study were published in the latest issue of the Journal of Neurology Neurosurgery and Psychiatry.

6 Mar 2019

Daily cup of cocoa may reduce tiredness in multiple sclerosis

A new study has shown that drinking a cup of flavonoid-enriched cocoa each day could help to reduce fatigue in people suffering from multiple sclerosis.

5 Mar 2019

New technique using patients' own modified cells could help treat Crohn's disease

A new technique using patients' own modified cells to treat Crohn's disease has been proven to be effective in experiments using human cells, with a clinical trial of the treatment expected to start in the next six months.

15 Feb 2019

Beer before wine does not change hangover severity

Despite popular belief, drinking beer before wine does not reduce the severity of veisalgia, otherwise known as a hangover, the following day.

8 Feb 2019

Study: Diagnosis delays for patients with lymphoma could be avoided

Many patients with lymphoma take longer to be diagnosed than expected, with some thinking these delays could have been avoided, a new report from the University of York has found.

30 Jan 2019

Study aims to help hospital staff manage fatigue when working at night shifts

Hospital staff are set to benefit from a new study that aims to help them manage the tiredness and fatigue they experience when working night shifts.

30 Jan 2019

Study shows hereditary hemochromatosis behind many cancers and joint diseases

A British study has found that “stealth disease”, also known as hemochromatosis, could be the reason behind several disease conditions including cancers and joint diseases.

20 Jan 2019

Consumption of hemp-containing foods can lead to exceedance of acute reference dose

On the basis of the available data, the BfR comes to the following conclusion: the consumption of hemp-containing foods with the total -Δ9-tetrahydrocannabinol (THC) levels on which the calculation is based can lead to an exceedance of the acute reference dose (ARfD) of 0.001 milligrams (mg) per kilogram body weight proposed by EFSA.

29 Nov 2018

FDA approves new treatment for AML patients

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older or who have other chronic health conditions or diseases (comorbidities) that may preclude the use of intensive chemotherapy.

22 Nov 2018

Survey: Complementary and alternative medicine is widely used by general population in England

Use of practitioner-led complementary and alternative medicine (CAM), such as acupuncture, massage, osteopathy and chiropractic treatment, rose from 12 per cent of the population in 2005 to 16 per cent of the population in 2015, according to a survey led by researchers at the University of Bristol's Centre for Academic Primary Care.

14 Nov 2018

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Genentech, a member of the Roche Group , announced today that the randomized Phase III CLL14 study, which evaluated fixed-duration Venclexta® in combination with Gazyva® in people with previously untreated chronic lymphocytic leukemia and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death compared to standard-of-care Gazyva plus chlorambucil.

1 Nov 2018

Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer

Genentech, a member of the Roche Group, today announced positive results from the Phase III IMpower130 study of Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of people with previously untreated metastatic non-squamous non-small cell lung cancer.

22 Oct 2018

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration has approved an update to the Rituxan® (rituximab) label to include information on follow up treatment of adult patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis who have achieved disease control with induction treatment.

22 Oct 2018